Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Endocrine 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Melanoma 6Breast Neoplasms 6Carcinoma, Renal Cell 5Lung Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Ovarian Neoplasms 2Neoplasms 2Liver Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Adenocarcinoma of Lung 2Adenocarcinoma Of Esophagus 2Adenocarcinoma 2Uveal Melanoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

Trastuzumab 2vandetanib 1tipifarnib 1spartalizumab 1fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Docetaxel 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × spartalizumab × Breast × Clear all
NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Novartis

Phase 1/2 Completed
319 enrolled 41 charts
BreastDermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡